- Price outlook for Injective (INJ) as Republic expands its integration of tokenization tools with Injective.
- The INJ token trades near $13.38 after dropping from highs around $16 amid a broader crypto sell-off.
- ETF expectations, tokenization growth and other catalysts could fuel an Injective bull run.
Injective is trading around $13.38 on Thursday evening, down roughly 3% over the past 24 hours and more than 12% lower on the week. With the recent integration between Injective and Republic, could INJ climb to $20?
Over the past week Injective has fallen from highs near $16 as marketwide selling pressure drove prices lower.
That pullback comes despite notable progress across the finance-focused layer-1 blockchain’s ecosystem.
With Republic — a leading tokenized investment platform — integrating with Injective, bulls may find fresh momentum if market sentiment turns positive.
Injective integrates with Republic
While the crypto market digests recent volatility, development continues behind the scenes.
Integrations are a key part of that work, and Injective has added a major one by officially integrating with Republic.
The platforms announced their partnership on August 21, aiming to bring Injective’s Layer 1 ecosystem into Republic’s on-chain investment infrastructure.
The collaboration focuses on enabling Injective-based projects to raise capital via Republic’s Launchpad, use the Republic Wallet for treasury management, and leverage Republic’s validator support.
Why this integration matters
Republic and Injective already had ties after Republic became an INJ validator, but this deeper integration advances the expansion of private markets on-chain.
“With 3 million+ community members across 150+ countries and a portfolio that includes 27 unicorns like SpaceX, Robinhood, Carta and Dapper Labs, Republic’s integration with Injective represents a pivotal moment in bridging traditional finance and on-chain innovation,” Injective wrote.
INJ price outlook: Can bulls retake $30?
Short-term technicals for INJ are leaning bearish, with indicators such as RSI and MACD favoring sellers.
Trading near $13 places Injective closer to its April 2025 low of $6.90 than to the recent peak of $34 reached in December 2024.
The marketwide sell-off that has impacted Bitcoin and altcoins has not helped bulls regain control.
However, if sentiment improves, a breakout to $20 could open the path for bulls to target the $30 area.
Beyond the Republic integration, key upside drivers include renewed institutional interest, continued growth in tokenization, and expanding real-world-asset activity on-chain.
Injective’s effort to introduce new financial primitives to broaden its DeFi capabilities — along with derivative markets such as Nvidia GPU contracts — adds to potential upside.
Optimism around ETF applications and expected approvals, as well as accumulation by large holders, would also support higher INJ prices.
Nonetheless, bulls need to maintain price support above roughly $13 — and ideally keep a floor near $10 — to avoid handing initiative back to the bears.